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Abstract
Background/Aims: The skeleton is a metabolically active organ undergoing continuous 
remodelling initiated by mesenchymal progenitors present in bone and bone marrow. Under 
certain pathological conditions this remodelling balance shifts towards increased resorption 
resulting in weaker bone microarchitecture, and there is consequently a therapeutic need to 
identify pathways that could inversely enhance bone formation from stem cells. Metabolomics 
approaches recently applied to stem cell characterisation could help identify new biochemical 
markers involved in osteogenic differentiation. Methods: Combined intra- and extracellular 
metabolite profiling was performed by liquid chromatography-mass spectrometry (LC-MS) 
on human mesenchymal stem cells (MSCs) undergoing osteogenic differentiation in vitro. 
Using a combination of univariate and multivariate analyses, changes in metabolite and 
nutrient concentration were monitored in cultures under osteogenic treatment over 10 days. 
Results: A subset of differentially detected compounds was identified in differentiating cells, 
suggesting a direct link to metabolic processes involved in osteogenic response. Conclusion: 
These results highlight new metabolite candidates as potential biomarkers to monitor stem 
cell differentiation towards the bone lineage.
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Introduction
Skeletal metabolism is an important aspect of healthy ageing, and bone loss, leading 
to osteopenia and bone fracture, has heavy consequences on quality of life and healthcare 
requirements. Bone mineral density is used to evaluate strength and predict fractures [1, 2]. 
Bone quality is characterized by its microarchitecture, turnover rate, micro-damage 
accumulation, calcification and bone matrix quality [3-5], however most standard bone 
monitoring systems do not accurately reflect the metabolic status of the tissue [6, 7]. Recent 
clinical assays focus on the measurement of urine/blood levels of compounds reflecting bone 
metabolism such as calcium [8], however calcium deficiency is not always associated with 
bone loss [9]. While the measurement of biochemical markers such as deoxypyridinoline 
formed during collagen maturation already represents an important clinical parameter for 
osteopenia management [10, 11], advanced metabolomics approaches have been instigated 
for prediction and diagnosis applications [12].
Global metabolite profiling offers a comprehensive measurement of small biomolecules 
produced in living cells, excreted metabolites from the cells into their microenvironment 
and taken up by the cells from a culture medium [13, 14]. Especially, liquid chromatography-
mass spectrometry (LC-MS)-based metabolomics is a powerful analytical tool allowing 
the monitoring of alterations in cell metabolism and producing a rapid snapshot of the 
comprehensive physiological status of the cells. Furthermore, LC-MS-based approaches have 
been applied to the quantitative analysis of intracellular metabolites in biological samples, 
and extracellular metabolites and nutrients in cell cultures, including mouse mesenchymal 
stem cells (MSCs) [15].
The maintenance of bone mass and quality is regulated by osteoblasts; this cell type is 
replenished by the osteogenic differentiation of mesenchymal progenitors [16, 17]. MSCs 
are multipotent somatic progenitors able to differentiate into osteogenic, chondrogenic and 
adipogenic lineages [18]. Their capacities to generate new osteoblasts, the bone-forming cell 
type, and the possibility of harvesting them from bone marrow collections have made them 
a promising candidate for therapeutic approaches to skeletal repair [19]. Numerous in vitro 
studies have established the osteoinductive effect of treatments combining dexamethasone, 
ascorbic acid, and beta-glycerophosphate (βGP) to promote MSC differentiation [20-25]. In 
order to understand the association between intra and extrametabolic pathway changes 
occurring during osteogenic differentiation of human mesenchymal stem cells, global 
metabolite profiling was performed on both human MSC extracts and their cell culture 
media using LC-MS to identify intracellular and extracellular metabolite changes occurring 
during differentiation. A new set of differentially detected compounds of biological relevance 
was identified, highlighting the potential of LC-MS-based metabolomics approaches for the 
quantitative time-point analysis of human MSC differentiation.
Materials and Methods
Reagents were purchased from ThermoFisher Scientific (Hemel Hempstead, UK) unless otherwise 
stated.
Cell culture and differentiation
An immortalised cell line of human bone marrow mesenchymal stem cells (MSCs) [26] was seeded 
at density of 3x104 cells/ml in standard MSC medium consisting of Dulbecco’s Modified Eagle’s Medium 
(DMEM), 10% FCS, 1 mM L-glutamine, 1% non-essential amino acids and 10% antibiotics, and incubated at 
37°C in 5% CO2. For differentiation, confluent cells were treated with osteogenic medium (OS) consisting of 
standard MSC medium supplemented with 100 nm dexamethazone (Sigma-Aldrich, Gillingham, UK), 0.05 
mM L-ascorbic acid 2 phosphate (Acros Organics, Geel, Belgium) and 10 mM beta glycerophosphate (βGP, 
Sigma-Aldrich) for 21 days with medium changes every 2 days. Parallel cultures maintained in standard 
MSC medium were used as untreated controls (C).
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Metabolic activity assay and DNA quantitation
Metabolic activity was measured at days 7, 14 and 21 using a PrestoBlue Cell Viability assay. Medium 
was aspirated and 100 µl of 10% Presto Blue reagent in HBSS solution was added into each well for 50 min 
at 37°C, 5% CO2. The solution was then transferred into a new 96-well plate, and fluorescent excitation 
and emission were measured at 560 nm and 590 nm, respectively, using a TECAN infinite 200 plate reader. 
Cells were then washed with PBS three times; followed by the addition of sterile distilled water and 
3 cycles of freezing and thawing to insure nuclear rapture and DNA release. A DNA standard curve (Quant-
iT PicoGreen ds DNA assay Kit) was used to determine the concentration of DNA in each sample. 100 µl of 
λ DNA standard in buffer was added into each well and incubated for 5 min at RT in the dark. The reagent 
was then transferred into a 96-well plate flat bottom and fluorescent intensity was measured using a TECAN 
infinite 200 plate reader at 480 nm excitation and 520 nm emission.
Mineral deposition analysis and Alkaline Phosphatase activity assay
Calcium deposits were analysed using Alizarin Red staining. At each stated time point, cells from 4 
replicates were trypsinised and pellets were smeared onto glass slides, air dried, fixed with 100% methanol 
and washed with distilled water. Slides were incubated in 1% Alizarin Red staining solution (Sigma-
Aldrich) for 10 min at room temperature, and washed with distilled water until all excess stain had been 
removed. Mineral deposits were then observed using a Nikon Eclipse Ni90 light microscope. In parallel, 
Alkaline phosphatase (ALP) activity was measured using 100 µl SIGMA FAST p-Nitrophenyl Phosphate 
reagent (Sigma-Aldrich) for 20 min at 37°C, 5% CO2. 100 µl from each sample transferred to a 96-well plate 
were analysed in triplicate using an Infinite 200 plate reader to measure absorbance at 405 nm. Data are 
presented as mean ± standard deviation and presented using GraphPad Prism 7; statistical significance was 
analysed using two-way Annova with p < 0.05 considered significant.
Metabolite extraction
For intracellular metabolite extraction at day 0, 14 and 21, medium of each culture was aspirated and 
cells were washed with PBS pre-warmed at 37°C and quenched by 1 ml of pre-cooled methanol at -48°C. 
While flasks were kept on ice, cells were removed using a cell scraper and the suspension was transferred 
into pre-cooled fresh tubes. Extraction was then performed by four freeze/thaw cycles (flash frozen in liquid 
nitrogen for 1 min, thawed on ice and vortexed for 30 s). Samples were then centrifuged at 17,000 rpm at 
4°C for 10 min, transferred to pre-cooled tubes and stored at -80°C until LC-MS analysis [14].
For extracellular metabolite extraction at day 0, 14 and 21, 1 ml of culture medium was collected and 
centrifuged at 10,000 rpm for 5 min. 250 µl of the collected medium were transferred to a new tube for 
metabolite extraction and protein precipitation by adding 750 µl of cold methanol (-20°C) in a ratio of 4:1, 
then mixing vigorously and incubating at -20°C for 20 min. Extracts were centrifuged at 17,000 rpm for 
10 min at 4°C, transferred to pre-cooled tubes and stored at -80°C until LC-MS analysis. Samples of fresh 
standard MSC medium (C-blk) and OS medium (OS-blk) were processed in parallel as no-cell controls. All 
samples were prepared with six replicates, and the experiment was run as two successive independent 
repeats. An equal mixture of all samples was prepared as quality control for instrument performance 
assessment [27, 28].
LC-MS analytical methodology
For both the intracellular and extracellular metabolite profiling, LC-MS was performed on an Accela 
system coupled to an Exactive MS (Thermo Fisher Scientific, Hemel Hempstead, UK) as previously described 
[28, 29]. Briefly, capillary voltage was 40 V (ESI+) and 30 V (ESI-), the spray voltage was 4.5 kV (ESI+) 
and 3.5 kV (ESI-), skimmer voltage was 20 V (ESI+) and 18 V (ESI-) and tube lens voltage was 70 V for the 
both modes. The temperature for capillary and probe was maintained at 275°C and 150°C, respectively. 
Intracellular and extracellular metabolites were separated on ZIC-pHILIC (4.6 × 150 mm and 5 μm particle 
size, Merck Sequant, Watford, UK). Chromatographic separation was carried out according to a linear 
gradient as following: 0–15 min (20% A – 20 mM ammonium carbonate in water; 80% B – acetonitrile), 
15–17 min (95% A), and 17–24 min (20% A) at 300 μl/min flow rate. The injection volume of 10 μl and the 
column was kept at 45°C.
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Metabolite identification and data analysis
Metabolites were processed with XCMS for untargeted peak-picking [30], and peak matching and 
annotation of related peaks were carried out using mzMatch [31]. IDEOM was used for putative metabolite 
identification and noise filtering with default parameters [32]. Metabolites were identified with four levels of 
confidence; level 1 identification was based on accurate masses and retention times of authentic standards, 
level 2 identification was based on accurate masses and predicted retention times. The identification criteria 
were according to a minimum reporting standard from the metabolomics standards initiative [33, 34].
Orthogonal partial least squares-discriminant analysis (OPLS-DA) was carried out using Simca P+13 
(Umetrics, Umeå, Sweden) (i) for general visualisation of metabolite differences between control medium 
samples and their controls, and OS treated medium samples and their blanks, (ii) to identify the temporal 
shift within control and OS treated conditions, and (iii) to observe the differences between control and 
OS treated medium samples (n = 6 in each group). Mass ions for discriminant biomarkers were selected 
by variable importance in projection values (VIP), where VIP values > 1 were considered as potential 
biomarkers. Cross-validation using the leave-one-out method was employed to evaluate the robustness of 
the generated OPLS-DA models based on the fitness of model (R2Y) and predictive ability (Q2) values [35]. 
Variable importance in the projection (VIP) based on OPLS models was used to determine key metabolites 
responsible for the metabolic difference between control and osteogenic treatment groups. Mass ions with 
VIP values greater than one were considered as significant metabolites which contributed to the separation.
Metabolic pathway and network analysis of discriminant metabolites putatively identified were 
performed using MetaboAnalyst 4.0 [36] and MetExplore [37]. The normalised abundances of the 
metabolites were Pareto scaled and processed for metabolite enrichment and pathway analysis. Metabolic 
pathway mapping was based on KEGG database with ‘Homo sapiens’ selected as a biosource for MetExplore 
platform.
Results
In vitro model of osteogenic differentiation
Osteogenic differentiation of human mesenchymal stem cells (MSC) was performed in 
vitro using an established osteogenic treatment [22] to model the cellular changes occurring 
upon osteogenic induction (Fig. 1). Cell growth, alkaline phosphatase activity (ALP) and 
mineral content were analysed to evaluate the osteogenic response over 3 weeks. No 
mineralisation was detected with standard medium, whilst OS conditions showed a time-
dependent increase in mineral deposition at day 14 and day 21 (Fig. 1A), confirming the 
differentiation response. ALP activity levels increased at early time-points, with significant 
upregulation at day 7 followed by a notable decline toward day 21 (Fig. 1B), in line with 
previous reports [22, 38, 39]. Metabolic activity showed a significant increase in OS-treated 
conditions compared to untreated controls at day 7, which was not maintained at 14 and 21 
days (Fig. 1C).
Multivariate analysis of intracellular and extracellular metabolites
To investigate the intracellular and extracellular changes occurring in the MSC cultures 
over the differentiation treatment, samples were collected at day 14 and 21 and analysed by 
LC-MS. Results were pre-processed into 2D matrix by mzMatch to introduce exact masses and 
retention times. OPLS-DA was then performed to determine the overall biological variation 
between all conditions, and to identify noticeable trends upon conditioning with MSCs over 
the course of the OS treatment (Fig. 2).
OPLS-DA scores plots showed reproducible clustering of biological replicates for each 
sample group, and highlighted clear differences between the different culture conditions 
tested. Analysis of intracellular metabolites showed distinct clusters from control and OS 
treated MSC at different time-points, with R2 and Q2 values of 0.841 and 0.644, respectively 
(Fig. 2A). These values indicate that the models are less likely to be overfitted as they are 
higher than the recommended values of 0.50 of Q2 for a robust model [35]. For extracellular 
metabolites, the non-conditioned fresh media (blanks) analysed without cells showed 
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distinct clusters from each medium sample 
conditioned in the presence of MSCs (Fig. 
2B). Samples exposed to OS medium 
clustered in a different quadrant from the 
control medium samples in the OPLS-DA 
scores plot with R2 and Q2 values of 0.942 
and 0.796, respectively. This multivariate 
analysis highlighted dynamic changes in 
the MSC culture medium over time in both 
standard and OS medium conditions, with 
datasets at earlier culture stages (day 0 and 
14) showing closer metabolomic proximity 
than at the later time-point (day 21).
Intracellular metabolite profiling of 
MSC under OS condition
Metabolomic differences between 
intracellular metabolites produced under 
standard and OS treatment were identified 
by combining OPLS-DA and univariate 
one-way ANOVA [28] and revealed 
308 intracellular compounds initially 
detected, with 31 intracellular metabolites 
showing an increase specifically during 
OS differentiation (Table 1). In particular, 
a subset of metabolites involved in amino 
acid metabolism was identified and 
showed significant increase during OS 
differentiation compared to the control 
medium condition (Fig. 3).
L-Lysine and L-proline levels, which 
were already detectable at day 0, showed 
a significant increase under OS treatment 
compared with control conditions (Fig. 3A, 
E). Other metabolites such as N6-(L-1,3-
dicarboxyprolyl)-L-lysine, L-pipecolate, L-2-
aminoadipate, L-glutamate 5-semialdehyde 
and N-acetylputrexcine (Fig. 3B, C, D, F and 
J) showed low concentration levels at day 0, 
which increased over time, maintaining a 
striking difference between elevated levels 
in OS medium compared to the control 
medium (Fig. 3B-D). Other compounds such 
as L-citrulline, 4-hydoxy-2-oxoglutarate, 
L-tyrosine, L-histidine, L-methionine, 
L-methionine S-oxide, N(pi)-methyl-L-histidine, S-adenocyl L-methionine and L-adrenaline 
also showed a significant increase under OS conditions which was maintained throughout 
the treatment duration (Fig. 3G, I, L, M, N, O and Q).
Fig. 1. Assessment of differentiation in MSC cultures 
treated with standard (white bars) or osteogenic 
(black bars) medium at day 7, 14 and 21 of differen-
tiation, with quantification of (A) Alizarin Red stain-
ing, (B) ALP activity and (C) metabolic activity.  All 
data in A, B and C are normalized to DNA content. 
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Extracellular metabolite profiling of MSC under OS condition
Further investigation was carried out by combining OPLS-DA and univariate one way 
ANOVA [28] to identify metabolomic differences between extracellular metabolites under 
standard and OS treatment. Out of 312 compounds initially detected, 10 extracellular 
metabolites showed significant increase under OS treatment (Table 1).
Fig. 2. OPLS-DA scores plots of metabolic profiles from MSC cell extracts (intracellular)(A), and their cul-
ture medium samples (extracellular)(B). (A) OS-treated MSC extracts (OS) after 14 (yellow) and 21 (light 
blue) days and their respective untreated MSC controls (C) after 0 (green), 14 (dark blue) and 21 (red) days 
in culture (R2 = 0.841 and Q2 = 0.644). (B) OS-treated MSC-conditioned medium samples after 14 (orange) 
and 21 (brown) days in culture, with their corresponding OS medium-only blank (OS-bk, purple), alongside 
control MSC medium samples after 0 (light blue), 14 (red) and 21 (yellow) days in culture, and their cor-
responding control medium-only blank (C-bk, blue) (R2 = 0.942 and Q2 = 0.796). Dashed arrows illustrate 
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Table 1. Metabolites showing the most significant fold change during OS differentiation of MSCs compared 
to untreated controls analysed by OPLS-DA and one-way ANOVA. * = compound not identified, & = compound 
increasing over time, § = compound showing significant change
 
β
Figure 3Fig. 3. Intracellular metabolite 
changes identified in the culture 
medium. Metabolites found to in-
crease over time in culture medi-
um from MSCs under OS treatment 
(OS) or from cells in control medi-
um (C) at day 0, 14 and 21 of treat-
ment. (****p<0.0001, ***p<0.001, 
**p<0.01; n=3).
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Metabolites such as (R, R)-tartaric acid and vinylacetylglycine were present in medium 
only blank of both untreated and OS treated conditions with no significant differences 
within D0, 14 and 21 of untreated control, while a significant increase was detected in the 
conditioned medium during OS treatment (Fig. 4A, E). Glycerol on the other hand, was 
present only during OS treatment but was absent in medium only blanks, D0, 14 and 21 on 
untreated control. However, a reduction toward D21 of OS was also observed (Fig. 4B). Other 
metabolites that presented only during OS treatment and sharply increased toward D21 
were hydantoin-5-propionate, D-glucarate and gamma-glutamylglutamic acid (Fig. 4G, J). 
4-imidazone-5-propanoate,3-(4-hydroxyphenyl) lactate and L-2-aminoadipate and N6-(L-
1,3-dicarboxypropyl)-L-lysine were absent in the medium only blanks and at D0, but gradual 
increase with untreated control was shown at D14 and continued toward D21. Interestingly, 
with OS condition a significant increase was detected throughout the treatment time point 
(Fig. 4D, F, H and I).
Fig. 4. Extracellular metabolite 
changes identified in the culture 
medium. Metabolites found to in-
crease over time in culture medi-
um from MSCs under OS treatment 
(OS) or from cells in control medi-
um (C) at day 0, 14 and 21 of treat-
ment, compared to levels found 
in corresponding no-cell medium 
blanks (OS-bk and C-bk, respec-
tively). (****p<0.0001, ***p<0.001, 
**p<0.01; n=6).
Fig re 4
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Discussion
Intracellular and extracellular metabolite profiling of osteogenic MSC differentiation
MSCs were treated to induce osteogenic differentiation in vitro, as evidenced by the 
induction of mineral deposition and ALP level over 3 weeks in culture, in line with previous 
observations on this model [40]. The LC-MS analysis of differentially regulated intracellular 
and extracellular metabolites under standard and OS treatment identified compounds 
that have never, to our knowledge, been linked with MSC osteogenesis in the literature. 
The multidimensional analysis revealed a significant elevation of (R, R)-tartaric acid, 
D-glucarate, glycerol, hydantoin-5-propionate, vinylacetylglycine, hydroxy-phenyllactate 
and 4-Imidazolone-5-propanoate in OS spent medium compared to the untreated condition.
Role of L-lysine in osteogenic differentiation
Intracellular metabolites analysis of OS-treated cells showed increases in compounds 
such as N6-(L-1,3-dicarboxypropyl)-L-lysine also known as saccharopine, L-pipecolate and 
L-2-aminoadipade, which are linked to lysine degradation (KEGG PATHWAY: MAP00310), 
and have not thus far been linked to stem cell proliferation and differentiation. Lysine is 
an essential amino acid and precursor for protein synthesis that cannot be synthesised by 
mammalian cells [41] and is one of the standard constituents of MSC culture medium. Here, 
some of its degradation pathway metabolites increased significantly during OS differentiation 
compared to untreated MSCs. In mammals, lysine degradation has two main routes, the first 
combining with α-ketoglutarate followed by the conversion to N6-(L-1,3-dicarboxypropyl)-
L-lysine (or saccharopine) (KEGGE REACTION: R00715) in liver and kidneys [42], and 
the second by the conversion to L-pipecolate (KEGG REACTION: R00459) in brain and 
contributing to not only the general nitrogen balance but also the controlled conversion 
of lysine into ketone bodies [43, 44]. The excessive amount of saccharopine in urine, or 
saccharopinuria, is a disease caused by impaired lysine degradation [45]. In addition, L-2-
aminoadipade, another metabolite in the lysine pathway with a role during skin collagen 
formation [46], was seen to increase in OS conditions alongside N6-(L-1,3-dicarboxypropyl)-
L-lysine. The joint intracellular and extracellular increase of these two compounds during OS 
treatment might underline a key role of lysine not only in energy production [47] but also 
in OS differentiation, possibly through collagen synthesis [48]. Therefore, such metabolites 
could be evaluated more comprehensively as potential bone metabolism biomarkers.
Role of proline and arginine
Another notable change in intracellular metabolite levels during OS treatment 
links to arginine and proline metabolism, as L-glutamate-5-semialdehyde, L-citrulline, 
S-adenosyl-L-methionine, 4-hydroxy-2-oxglutarate and N-acetylputrescine all increased 
upon differentiation (KEGG PATHWAY: MAP00330). Proline is a non-essential amino acid 
synthesized from glutamic acid and is a crucial component of collagen [49, 50], while 
arginine plays an important role during bone healing through the production of nitric oxide 
(NO) and conversion into L-citrulline [51]. In addition, L-citrulline is formed alongside 
orthophosphate by catalysing carbamoyl phosphate and ornithine (KEGG REACTION: 
R01398). L-Glutamate-5-semialdehyde is the metabolic precursor for proline biosynthesis 
that can be converted to or be formed from L-proline (KEGG ENZYNE: EC 1.5.99.8 and 
EC 1.5.1.2), alongside orthophosphate (KEGG REACTION: R 03313). Interestingly, we 
previously reported that mouse MSCs OS differentiation was accompanied by an increase 
in orthophosphate extracellular level [28], which might support the biological interaction of 
these compounds during bone formation.
S-Adenosyl-L-methionine is a methyl donor with anti-inflammatory effects [52, 53] 
and N-acetylputrescine is a downstream arginine metabolite upregulated in neural stem 
cells [54]. While their association with bone formation has not been reported before, here 
intracellular levels of these two compounds were measured to increase upon OS treatment, 
calling for future evaluations in vitro and in vivo. In contrast, medium measurements 
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showed that L-glutamate-5-semialdehyde, L-citrulline, 4-hydroxy-2-oxglutarate and 
N-acetylputrescine showed no significant differences in their extracellular level compared to 
untreated control (data not shown). This may suggest that some metabolites produced during 
proline and arginine metabolism play an intracellular role during osteogenic differentiation. 
It is also interesting to note that N-acetylputrescine and S-adenosyl-L-methionine were not 
identified extracellularly, which could be due to technical limitations or might indicate their 
degradation inside the cells.
Role of amino acids
LC-MS also identified metabolic changes related to wider amino acid metabolism were 
significantly elevated intracellularly and extracellularly during OS treatment compared to 
the untreated condition.
Hydantoin-5-propionate, a metabolite of histidine (KEGG PATHWAY: map00340), 
significantly increased in the extracellular space during osteogenic treatment. Since 
histidine was one of the amino acids seen to significantly increase intracellularly during 
the differentiation treatment, it would be consistent with the production of hydantoin-5-
propionate and indicate it as a compound of interest for osteogenic monitoring.
4-Imidazolone-5-propanoate is another histidine metabolite (KEGG PATHWAY: 
map00340) that increased extracellularly during OS differentiation. It is produced from 
urocanic acid by the enzyme urocanate hydratase [EC: 4.2.1.49], and is also converted to 
N-forminimo-L-glutamate by the enzyme imidazolonepropionase [EC: 3.5.2.7]. N-forminimo-
L-glutamate is then converted to glutamate, which links to proline metabolism through 
L-1-Pyrroline-5-carboxylate (KEGG PATHWAY: map00330). An increase in intracellular 
L-glutamate-5-semialdehyde was revealed during our intracellular metabolite analysis, 
which could possibly reflect the role of histidine during proline metabolism, starting with 
extracellular conversion of histidine into 4-imidazolone-5-propanoate and then conversion 
of glutamate into L-glutamate-5-semialdehyde intracellularly to start proline metabolism.
Role of osteogenic medium components
Ascorbic acid is an essential compound for collagen synthesis [50], as it couples with 
2-oxoglutarate to form a cofactor for proly 3-hydroxylase and proly 4-hydroxylase enzymes to 
hydrolyse proline (KEGG: EC 1.14.1.2) and produce hydroxyproline (KEGG: R03219) during 
collagen synthesis. Interestingly, our data showed a significant increase in (R, R)-tartaric 
acid in spent medium during osteogenic treatment compared to medium from untreated 
controls. (R, R)-tartaric acid is an organic acid involved in glyoxylate and dicarboxylate 
metabolism (KEGG PATHWAY: map00630), which links to ascorbate and aldarate metabolism 
(KEGG PATHWAY: map00053). Recent studies reported the effect of L-tartaric acid on the 
improvement bone cement mechanical toughness [55], pointing to a possible usefulness for 
bone applications.
Glycerol, which is produced by the degradation of βGP, component of the OS medium, 
by the glycerol 3-phosphatase enzyme to glycerol and orthophosphate during glycerolipid 
metabolism (KEGG REACTION: R00841) (KEGG ENZYME: EC 3.1.3.19), was seen to 
significantly increase in the extracellular medium during OS treatment. In agreement with 
previous observations in mouse cell cultures [28], higher glycerol levels were consistently 
detected in the osteogenic differentiation time-course of human MSCs. This is an interesting 
observation in light of a recent preclinical study, which reported the potential of glycerol in 
maintaining biochemical strength of bone graft in rat [56].
Our analysis was also detected compounds that have never been linked to the osteogenic 
process, such as vinylacetylglycine and hydroxy-phenyllactate. Vinylacetylglycine is part 
of acyl glycines which are minor fatty acids (HMDB00894) and hydroxy-phenyllactate is a 
metabolite involved in phenylalanine and tyrosine metabolism. Our LC-MS analysis revealed 
elevation in both metabolites at late stages of OS treatment compared with untreated 
control. Though there is no reported data linking this metabolite to bone formation, hydroxy-
phenyllactate was recently detected by LC-MS technology as a compound in human breast 
milk [57]. Thus further investigation is needed to probe their role during osteogenesis.
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Metabolomics approaches uncover new facets of differentiation
To the best of our knowledge, this study provides the first comprehensive LC-MS 
analysis showing significant changes in intra- and extracellular metabolites occurring 
during OS treatment of MSCs. Recently, a GC-MS volatolomic analysis was conducted to 
evaluate the effects of dexamethasone and BMP-2 on human umbilical cord blood MSCs 
during osteogenesis [58]. In that particular study, serine, threonine, and methionine 
concentrations were observed to significantly increase at an early time point (day 7), while 
TCA cycle metabolites were significantly reduced with both dexamethasone and BMP-2 
treatments. This echoes our LC-MS results for intra- and extracellular metabolite profiles, 
which identified a set of amino acids that significantly increased during OS induction, while 
metabolites from the TCA cycle were reduced.
Furthermore, this dual metabolite analysis highlights an interesting link to pathways 
that could contribute to MSC differentiation such as lysine degradation and proline 
metabolism, and other amino acids that may play a crucial role in skeletal development 
(see summary in Fig. 5). The culture model used here represents a relevant system to study 
human osteogenesis in vitro [59-61], and thus enabled the identification of new candidate 
metabolites of relevance to primary mesenchymal progenitors responsible for the bone 
repair process in vivo. In order to exploit these results, it will be necessary to further quantify 
the concentration of these specific metabolites over time and test their potential effect on 
the formation of skeletal tissue in vitro and in vivo.
Fig. 5. Summary of meta-
bolic pathways revealed 
by the significant changes 
in metabolites detected 
in MSC finger- and foot-
printing. (A) Genome scale 
metabolic network analy-
sis: red-filled circles show 
the significant metabolites 
used as input, green circles 
represent metabolites re-
sulting from the network 
construction and rectan-
gles represent reactions 
(connecting enzymes). (B) 
Pathway analysis: the top 
pathways were ranked by 
the gamma-adjusted p-
values for permutation per 
pathway (y-axis) and the 
total number of hits per 
pathway (x-axis). Colour 
graded from white to red, 
circle size (large > small) 
as well as the values of both 
x and y increase represent 
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Since some of the identified metabolites represent new potential markers alongside 
existing bone markers for the clinical monitoring of bone metabolism [62, 63], it could be 
useful to integrate stable isotope assisted metabolomics to a broader metabolic profiling 
approach [64], as performed for instance for glycerol by tracing triglycerides (TG) in vitro to 
study human liver lipid metabolism [65].
The interaction between intracellular and extracellular metabolites during collagen 
synthesis could similarly be performed by tracing compounds such as L-2-aminoadipade 
(intra/extracellular) and N6(L-1,3-dicarboxypropyl)-L-lysine (intra/extracellular) on lysine 
metabolism. As this study relied on the evaluation of mineral deposition and ALP levels to 
monitor osteogenic differentiation in culture, it could be useful in the future to also explore 
the expression of extracellular matrix proteins such as collagen I and osteocalcin [62] to 
provide a finer correlation with the changes in cell phenotype during time-course of the 
differentiation. It would equally be of interest to compare these results to the metabolomic 
fingerprint achieved when exposing cells to additional pro-osteogenic inducers, and 
correlate these with the differentiation response achieved in vitro. Recent LC-MS-based 
analyses applied to in vitro models have uncovered new metabolite signatures of clinical 
relevance for specific developmental [66] or disease processes [67], underlining the benefits 
of such unbiased metabolomics approaches.
Beyond the measurement of calcium levels [8] routinely used in the field, such a 
metabolomics approach could thus add new candidates to support the monitoring of bone 
differentiation in preclinical models, and provide potential markers of bone metabolism for 
clinical applications.
Conclusion
The osteogenic potential of MSCs has yielded a number of applications in regenerative 
medicine and drug discovery to target conditions such as osteoporosis and other conditions 
where bone tissue is compromised. Here, a combined metabolomics approach was performed 
to analyse both dynamic intracellular and extracellular metabolite changes occurring in MSCs 
undergoing osteogenic differentiation, to capture broad metabolomics changes and identify 
differentiation-related compounds. This approach identified new MSC-differentiation 
related compounds which point to specific pathways relevant to bone metabolism, such 
as those involved in lysine and proline metabolism. Metabolites identified here could now 
be further analysed in other osteogenic cultures such as primary MSCs and HES cultures 
[68], as well as iPS-derived progenitors prepared from different donor origin [69]. Such 
intra and extracellular chemosignals released by stem cells could indicate novel biological 
pathways underpinning osteogenesis, and could represent new osteogenic biomarkers for 
osteogenesis monitoring and diagnostics for bone-related conditions.
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